 Steve, I don't know where to begin. We've got major Q4 results and 2022 numbers, which are just purely outstanding. Where would you like to start? Well, I guess as you started, Tracy, first off, it's great to be back on your shows. I truly enjoy our conversations that we've had over the last few years. Q4 for Valeo, which ended October 31st, was by far our best quarter ever. $12.7 million of revenue has probably doubled the best quarter we've ever had before. Internal growth, product acquisition, and we see it continuing. The year overall, $27.7 million. Again, another doubling from the year prior. We expect that again to double this year. Our projections are in the low 60s in terms of our revenue for 23. So I think our story can be summed up with growth and more growth. And in speaking to your record, Q4 results, they were up 274% over Q4 2021. Your news release was outstanding in the way that it was written. You had a highlight section for what you did in Q4 that made these financial results a reality. Can you talk to our investors and the investor intel audience about what you guys did to make these numbers happen? Well, Q4 was the culmination of a lot of work on our existing products. So the organic growth of our existing products, Redesca, Ender's Air for Asthma, and Sectura for Asthma certainly played a big part. But just prior to the beginning of Q4, we actually, we acquired three additional products that were accretive from day one. And the two of them are, you know, Ophthalmology, Zidra, and Symbrinza. One of them in severe allergic reactions, Allergek, which is an innovative delivery system for epinephrine. So all of those are, we call them our big six. We have a dozen products, but really those big six are the ones that are driving our growth. And we saw it in Q4 and you'll see it again in Q1, where, which we've already come out and said that Q1 will be better than Q4. Our Q, our first quarter of their fiscal year just ended on January 31st. But, and we expect that to continue throughout the year. You said the big six, but in your quote, you talk about acquiring the rights to three growth assets. So what are the other three? Walk us through the big six. The big six for us are where we, you know, as I've mentioned to you before, and we've talked about how it is that a pharma company succeeds and grows its revenues. And a lot of it is its people. It's people that deal with all the various elements, but one of them is clearly the commercial side. We have 85 commercial representatives in the field. Seeing doctors, healthcare professionals, hospitals, every single day. That's a huge number actually for the company of our size. So the big six are the products that we currently promote with our field team. First being Redesca, which is a hospital product and anti-quaggling, a blood thinner essentially. The second two, which are our diamonds, which are Enterzair and Attic Turra, and certainly Enterzair, we believe is has a strong potential in asthma and will become our first $100 million revenue product. And the other three are the newly acquired ones, the two in ophthalmology. So that's a new area for us. We've created a new ophthalmology business unit, fully staffed. And the third of the ones we recently acquired or the sixth overall is Allergek, which is our epinephrine, out severe allergic reaction auto-injector. So those are the ones that we put all of our, when I say commercial activities, we support all our products commercially. But they're the ones that received the bulk of the attention of our field team, which as I mentioned is over 80 people. So for everyone out there who missed the story about the 2022 revenues for Vallejo Pharma, which were up 105% 27.7 million for the year ended October 31st, compared to 13.6 million for the year ended October 31st, 2021. Thank you so much, Steve, for your update and congratulations on both your Q4 and your 2022 results. Thanks, Tracy. Good to see you.